Advances in Treatment of Triple Negative Breast Cancer
10.3971/j.issn.1000-8578.2022.21.1323
- VernacularTitle:三阴性乳腺癌的治疗进展
- Author:
Yikun KANG
1
;
Peng YUAN
Author Information
1. Department of VIP Medical Services, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Research Article
- Keywords:
TNBC;
BRCA gene;
Chemotherapy;
Immunotherapy
- From:
Cancer Research on Prevention and Treatment
2022;49(8):812-819
- CountryChina
- Language:Chinese
-
Abstract:
TNBC is a special type of breast cancer with strong aggressiveness and poor prognosis. Chemotherapy is still the main treatment for TNBC, due to poor efficacy of endocrine therapy and targeted therapy. However, TNBC is a kind of heterogeneous disease, so it is urgent to study the precise molecular types and explore new precision treatment. This paper will summarize the results of clinical trials and analyze treatment strategies for TNBC, including surgical treatment, radiotherapy, chemotherapy, targeted therapy and immunotherapy, in order to provide evidence for clinical management.
